<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00109993</url>
  </required_header>
  <id_info>
    <org_study_id>CASE1Z04</org_study_id>
    <secondary_id>P30CA043703</secondary_id>
    <secondary_id>CASE-CWRU-1Z04</secondary_id>
    <secondary_id>CWRU-060419</secondary_id>
    <secondary_id>CASE-1Z04</secondary_id>
    <nct_id>NCT00109993</nct_id>
  </id_info>
  <brief_title>Campath-1H + FK506 and Methylprednisolone for GVHD</brief_title>
  <official_title>Phase II Clinical Trial Incorporating Alemtuzumab (Campath-1H) in Combination With FK506 and Methylprednisolone for Treatment of Severe Acute Graft vs Host Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Case Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Case Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Alemtuzumab, tacrolimus, and methylprednisolone may be an effective treatment for
      graft-versus-host disease caused by a donor stem cell transplant.

      PURPOSE: This phase II trial is studying how well giving alemtuzumab together with tacrolimus
      and methylprednisolone works in treating acute graft-versus-host disease in patients who have
      undergone donor stem cell transplant.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Determine the 4-week rate of complete response in patients with severe acute
           graft-vs-host disease (GVHD) treated with alemtuzumab, tacrolimus, and
           methylprednisolone within 100 days after undergoing allogeneic stem cell
           transplantation.

      Secondary

        -  Determine the best response at 4 and 12 weeks in patients treated with this regimen.

        -  Determine 6-month survival of patients treated with this regimen.

        -  Determine the rate of infectious complications in patients treated with this regimen.

        -  Determine rate of chronic GVHD in patients treated with this regimen.

      OUTLINE: This is an open-label, single-blind, multicenter study.

      Patients receive methylprednisolone IV on days 1-3 and then orally or IV on days 4-14;
      tacrolimus IV continuously on days 1-7 and then orally once or twice daily on days 8-180,
      followed by a taper in the absence of chronic graft-vs-host disease; and alemtuzumab IV over
      2 hours on days 4-6, 18, and 32. Treatment continues in the absence of unacceptable toxicity
      or the development of serious infection.

      After completion of study treatment, patients are followed at 2 and 4 weeks.

      PROJECTED ACCRUAL: A total of 9-34 patients will be accrued for this study within 8-12
      months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">May 2007</completion_date>
  <primary_completion_date type="Actual">June 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Graft-vs-host disease response</measure>
    <time_frame>1, 2, 3, and 4 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of serious infections by clinical, radiologic, and microbiologic assessments</measure>
    <time_frame>1,2,3, and 4 months</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">34</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Chronic Myeloproliferative Disorders</condition>
  <condition>Gestational Trophoblastic Tumor</condition>
  <condition>Graft Versus Host Disease</condition>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Myelodysplastic/Myeloproliferative Diseases</condition>
  <condition>Neuroblastoma</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Testicular Germ Cell Tumor</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>alemtuzumab</intervention_name>
    <description>alemtuzumab IV over 2 hours on days 4-6, 18, and 32</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methylprednisolone</intervention_name>
    <description>methylprednisolone IV on days 1-3 and then orally or IV on days 4-14</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tacrolimus</intervention_name>
    <description>tacrolimus IV continuously on days 1-7 and then orally once or twice daily on days 8-180, followed by a taper in the absence of chronic graft-vs-host disease</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Diagnosis of acute graft-vs-host disease (GVHD)

               -  Clinical grade C or D disease

                    -  No grade C disease with single organ skin involvement

          -  Has undergone allogeneic stem cell transplantation within the past 100 days

               -  Absolute neutrophil count &gt; 500/mm^3 (donor-derived [&gt; 60% by peripheral blood
                  lymphocyte chimerism analyses])

          -  No development of GVHD after prior donor lymphocyte infusion

          -  Must have received prior prophylactic cyclosporine or tacrolimus at the onset of acute
             GVHD

        PATIENT CHARACTERISTICS:

        Age

          -  Over 18

        Performance status

          -  Not specified

        Life expectancy

          -  Not specified

        Hematopoietic

          -  See Disease Characteristics

        Hepatic

          -  No serologic evidence of active hepatitis B or C infection

        Renal

          -  Creatinine â‰¤ 3.5 mg/dL

          -  No requirement for dialysis

        Cardiovascular

          -  No requirement for vasopressors

        Pulmonary

          -  No requirement for a ventilator

        Other

          -  Not pregnant

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception during and for 6 months after
             completion of study treatment

          -  No known HIV positivity

          -  No active uncontrolled infection

          -  No other organ dysfunction

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  See Disease Characteristics

        Chemotherapy

          -  Not specified

        Endocrine therapy

          -  Not specified

        Radiotherapy

          -  Not specified

        Surgery

          -  Not specified
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mary Laughlin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mt. Sinai Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106-7284</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health Sciences University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western Pennsylvania Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Transplant Institute</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 3, 2005</study_first_submitted>
  <study_first_submitted_qc>May 3, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2005</study_first_posted>
  <last_update_submitted>June 10, 2010</last_update_submitted>
  <last_update_submitted_qc>June 10, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 11, 2010</last_update_posted>
  <responsible_party>
    <name_title>Mary Laughlin, MD</name_title>
    <organization>Ireland Cancer Center at University Hospitals Case Medical Center,Case Comprehensive Cancer Center</organization>
  </responsible_party>
  <keyword>graft versus host disease</keyword>
  <keyword>accelerated phase chronic myelogenous leukemia</keyword>
  <keyword>adult acute lymphoblastic leukemia in remission</keyword>
  <keyword>adult acute myeloid leukemia in remission</keyword>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>adult acute myeloid leukemia with inv(16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(15;17)(q22;q12)</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(8;21)(q22;q22)</keyword>
  <keyword>atypical chronic myeloid leukemia</keyword>
  <keyword>blastic phase chronic myelogenous leukemia</keyword>
  <keyword>chronic eosinophilic leukemia</keyword>
  <keyword>chronic idiopathic myelofibrosis</keyword>
  <keyword>chronic myelomonocytic leukemia</keyword>
  <keyword>chronic neutrophilic leukemia</keyword>
  <keyword>chronic phase chronic myelogenous leukemia</keyword>
  <keyword>de novo myelodysplastic syndromes</keyword>
  <keyword>disseminated neuroblastoma</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <keyword>myelodysplastic/myeloproliferative disease, unclassifiable</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult Burkitt lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult immunoblastic large cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult lymphoblastic lymphoma</keyword>
  <keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II mantle cell lymphoma</keyword>
  <keyword>noncontiguous stage II marginal zone lymphoma</keyword>
  <keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
  <keyword>poor prognosis metastatic gestational trophoblastic tumor</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>recurrent adult acute lymphoblastic leukemia</keyword>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>recurrent adult Burkitt lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>recurrent adult Hodgkin lymphoma</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent adult lymphoblastic lymphoma</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>recurrent neuroblastoma</keyword>
  <keyword>recurrent ovarian epithelial cancer</keyword>
  <keyword>recurrent ovarian germ cell tumor</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>recurrent malignant testicular germ cell tumor</keyword>
  <keyword>refractory chronic lymphocytic leukemia</keyword>
  <keyword>refractory multiple myeloma</keyword>
  <keyword>refractory hairy cell leukemia</keyword>
  <keyword>relapsing chronic myelogenous leukemia</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <keyword>secondary myelodysplastic syndromes</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <keyword>stage I multiple myeloma</keyword>
  <keyword>stage III adult Burkitt lymphoma</keyword>
  <keyword>stage III adult diffuse large cell lymphoma</keyword>
  <keyword>stage III adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage III adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage III adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage III adult lymphoblastic lymphoma</keyword>
  <keyword>stage II ovarian epithelial cancer</keyword>
  <keyword>stage III chronic lymphocytic leukemia</keyword>
  <keyword>stage III grade 1 follicular lymphoma</keyword>
  <keyword>stage III grade 2 follicular lymphoma</keyword>
  <keyword>stage III grade 3 follicular lymphoma</keyword>
  <keyword>stage III mantle cell lymphoma</keyword>
  <keyword>stage III marginal zone lymphoma</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <keyword>stage III ovarian epithelial cancer</keyword>
  <keyword>stage III small lymphocytic lymphoma</keyword>
  <keyword>stage III malignant testicular germ cell tumor</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>stage IIIB breast cancer</keyword>
  <keyword>stage IIIC breast cancer</keyword>
  <keyword>stage IV adult Burkitt lymphoma</keyword>
  <keyword>stage IV adult diffuse large cell lymphoma</keyword>
  <keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage IV adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage IV adult lymphoblastic lymphoma</keyword>
  <keyword>stage IV breast cancer</keyword>
  <keyword>stage IV chronic lymphocytic leukemia</keyword>
  <keyword>stage IV grade 1 follicular lymphoma</keyword>
  <keyword>stage IV grade 2 follicular lymphoma</keyword>
  <keyword>stage IV grade 3 follicular lymphoma</keyword>
  <keyword>stage IV mantle cell lymphoma</keyword>
  <keyword>stage IV marginal zone lymphoma</keyword>
  <keyword>stage IV ovarian epithelial cancer</keyword>
  <keyword>stage IV small lymphocytic lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Neuroblastoma</mesh_term>
    <mesh_term>Neoplasms, Germ Cell and Embryonal</mesh_term>
    <mesh_term>Graft vs Host Disease</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
    <mesh_term>Testicular Neoplasms</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
    <mesh_term>Trophoblastic Neoplasms</mesh_term>
    <mesh_term>Gestational Trophoblastic Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
    <mesh_term>Alemtuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

